JP7203015B2 - 免疫原性組成物 - Google Patents

免疫原性組成物 Download PDF

Info

Publication number
JP7203015B2
JP7203015B2 JP2019511574A JP2019511574A JP7203015B2 JP 7203015 B2 JP7203015 B2 JP 7203015B2 JP 2019511574 A JP2019511574 A JP 2019511574A JP 2019511574 A JP2019511574 A JP 2019511574A JP 7203015 B2 JP7203015 B2 JP 7203015B2
Authority
JP
Japan
Prior art keywords
influenza
amino acid
seq
region
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019511574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534242A5 (enExample
JP2019534242A (ja
Inventor
クレイグ トンプソン，
スネトラ グプタ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of JP2019534242A publication Critical patent/JP2019534242A/ja
Publication of JP2019534242A5 publication Critical patent/JP2019534242A5/ja
Priority to JP2022209044A priority Critical patent/JP7762643B2/ja
Application granted granted Critical
Publication of JP7203015B2 publication Critical patent/JP7203015B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019511574A 2016-08-25 2017-08-25 免疫原性組成物 Active JP7203015B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022209044A JP7762643B2 (ja) 2016-08-25 2022-12-26 免疫原性組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1614485.9 2016-08-25
GBGB1614485.9A GB201614485D0 (en) 2016-08-25 2016-08-25 Immunogenic composition
PCT/GB2017/052510 WO2018037246A1 (en) 2016-08-25 2017-08-25 Immunogenic composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022209044A Division JP7762643B2 (ja) 2016-08-25 2022-12-26 免疫原性組成物

Publications (3)

Publication Number Publication Date
JP2019534242A JP2019534242A (ja) 2019-11-28
JP2019534242A5 JP2019534242A5 (enExample) 2020-10-01
JP7203015B2 true JP7203015B2 (ja) 2023-01-12

Family

ID=57119951

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019511574A Active JP7203015B2 (ja) 2016-08-25 2017-08-25 免疫原性組成物
JP2022209044A Active JP7762643B2 (ja) 2016-08-25 2022-12-26 免疫原性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022209044A Active JP7762643B2 (ja) 2016-08-25 2022-12-26 免疫原性組成物

Country Status (8)

Country Link
US (2) US11123422B2 (enExample)
EP (1) EP3504235A1 (enExample)
JP (2) JP7203015B2 (enExample)
CN (1) CN109923125B (enExample)
AU (2) AU2017315238A1 (enExample)
CA (1) CA3034328A1 (enExample)
GB (1) GB201614485D0 (enExample)
WO (1) WO2018037246A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201614485D0 (en) * 2016-08-25 2016-10-12 Univ Oxford Innovation Ltd Immunogenic composition
BR112021005255A2 (pt) * 2018-09-21 2021-06-29 Board Of Regents Of The University Of Nebraska método de produção e uso de genes para vacina contra a influenza centralizada universal
GB2578163A (en) * 2018-10-19 2020-04-22 Univ Pretoria Plant produced avian influenza antigens and their uses in diagnostic assays and devices
GB202204478D0 (en) * 2022-03-29 2022-05-11 Univ Oxford Innovation Ltd Immunogenic compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
CA2035576A1 (en) 1990-02-07 1991-08-08 Alexander R. Neurath Conformational epitopes of human immunodeficiency virus envelope glycoprotein gp120 hiv-1
SI0851927T1 (en) * 1995-09-01 2004-02-29 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis
EP1490101A4 (en) * 2002-03-05 2006-09-20 Univ Texas PROCESS FOR IMPROVING IMMUNE INDUCTION WITH MDA-7
CN101193655A (zh) * 2005-04-11 2008-06-04 美国政府健康及人类服务部，疾病控制和预防中心 抗大流行性流感病毒株的疫苗
EP2522678A1 (en) 2006-05-15 2012-11-14 Sea Lane Biotechnologies, LLC Neutralizing antibodies to influenza viruses
WO2008021959A2 (en) * 2006-08-09 2008-02-21 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
JP5813505B2 (ja) 2008-07-18 2015-11-17 メディカゴ インコーポレイテッド 新規インフルエンザウイルス免疫エピトープ
WO2011126370A1 (en) 2010-04-09 2011-10-13 Universiteit Utrecht Holding B.V. Recombinant multimeric influenza proteins
US8900590B2 (en) * 2010-08-12 2014-12-02 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
EP3431100B1 (en) 2010-09-14 2021-09-08 University of Pittsburgh- Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
WO2013177444A2 (en) * 2012-05-23 2013-11-28 The Board Of Trustees Of The Leland Stanford Junior University Influenza vaccine constructs
US8932598B2 (en) * 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
AU2014245779B2 (en) 2013-03-28 2020-02-06 Aramis Biotechnologies Inc. Influenza virus-like particle production in plants
GB201614485D0 (en) * 2016-08-25 2016-10-12 Univ Oxford Innovation Ltd Immunogenic composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Journal of Virology，2012年，Vol. 86, No. 21，p. 11686-11697
Journal of Virology，2014年，Vol. 88, No. 12，p. 6743-6750
Journal of Virology，2014年，Vol. 88, No. 13，p. 7130-7144

Also Published As

Publication number Publication date
CN109923125B (zh) 2024-05-31
AU2024227680A1 (en) 2024-11-21
JP7762643B2 (ja) 2025-10-30
EP3504235A1 (en) 2019-07-03
WO2018037246A1 (en) 2018-03-01
US11123422B2 (en) 2021-09-21
US20190201521A1 (en) 2019-07-04
US12390518B2 (en) 2025-08-19
JP2019534242A (ja) 2019-11-28
US20220054625A1 (en) 2022-02-24
JP2023052092A (ja) 2023-04-11
GB201614485D0 (en) 2016-10-12
CA3034328A1 (en) 2018-03-01
CN109923125A (zh) 2019-06-21
WO2018037246A4 (en) 2018-04-19
AU2017315238A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
JP7762643B2 (ja) 免疫原性組成物
US20230165952A1 (en) Betacoronavirus prophylaxis and therapy
US12144857B2 (en) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
CN105452270B (zh) 流行性感冒病毒疫苗及其用途
US10729758B2 (en) Broadly reactive mosaic peptide for influenza vaccine
WO2020092207A1 (en) Broadly reactive immunogens of influenza virus, compositions, and methods of use thereof
JP2023522154A (ja) インフルエンザワクチン
WO2011024748A1 (ja) インフルエンザm2由来の改変ペプチドワクチン
CN116514991A (zh) 一种β冠状病毒和流感嵌合抗原、其制备方法和应用
US20240100148A1 (en) Broadly reactive viral antigens as immunogens, compositions and methods of use thereof
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン
WO2023187366A1 (en) Immunogenic compositions for the prevention of influenza a
CA3076263C (en) Synthetic hemagglutinin as universal vaccine against infection by type b influenza viruses (ibv)
KR101768600B1 (ko) 범용성 개 인플루엔자 바이러스 백신 조성물
CN112955171A (zh) 产生广泛反应、泛表位的免疫原、组合物的方法及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221226

R150 Certificate of patent or registration of utility model

Ref document number: 7203015

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150